Text Size

A randomized study of the efficacy and safety of 0.1% cyclosporine a cationic emulsion in treatment of moderate to severe dry eye

Baudouin C., Figueiredo F.C., Messmer E.M., Ismail D., Amrane M., Garrigue J.-S., Bonini S., Leonardi A.

  • 2017
  • European Journal of Ophthalmology
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Categories

    Clinical development

  • Affiliations

    Quinze-Vingts National Ophthalmology Hospital, Paris, France; Pierre et Marie Curie University, Paris 6, Vision Institute, INSERM UMR968, CNRS UMR7210, Paris, France; University of Versailles Saint-Quentin en Yvelines, Versailles, France; Royal Victoria Infirmary, Newcastle University, Newcastle upon Tyne, United Kingdom; Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany; Santen SAS, Evry, France; Campus Bio Medico, Università di Roma, Rome, Italy; Department of Neuroscience, Ophthalmology Unit, University of Padua, Padua, Italy

Related Publications

Burden of Vernal Keratoconjunctivitis in the United States: A Retrospective Claims Database Analysis

Koo E.B.; Yu T.M.; Layton A.J.; Babineaux S.; Fung S.

Review of clinical outcomes of a cationic emulsion tear substitute in patients with dry eye disease

Labetoulle M, Garhöfer G, Ismail D, Garrigue JS, Amrane M, Guillon M, Aragona P, Baudouin C.

Epinastine Cream: A Novel Once-Daily Therapeutic Agent for Allergic Conjunctivitis

Ogura N., Fujisawa K., Kato M.

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022